VRG Miniprotein Secures €4M Catalyst Grant to Advance Kv1.3 Program
We are proud to share that our Kv1.3 program has been selected for funding under the Life Sciences Catalyst Program – “From Proof of Concept to Clinical Trials (PoC to Clinic)” (2025-1.1.4-LIFE SCIENCES II.) by National Research, Development and Innovation Office.
Our Kv1.3 program has been awarded ~€4 million in funding (total program budget ~€5.8 million) to advance from proof-of-concept to first in human trials.
Introduction
WRITTEN BY
VRG Therapeutics
PUBLISHED ON
April 13, 2026
SHARE THIS ON
WRITTEN BY
VRG Therapeutics
PUBLISHED ON
April 13, 2026
SHARE THIS ON
Introduction
Latest
News
The latest industry news, interviews, technologies, and resources.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
